title: [Allergy-immunology. New therapies for acute attacks in hereditary angioedema].
abstract: Hereditary angioedema is a disease which develops as a result of a deficiency or dysfonction of C1-inhibitor, a key regulator of the complement, coagulation and contact cascades, resulting among others in excessive release of bradykinin. This disease mortality rate is high in absence of immediate and effective treatment, in particular in presence of acute attacks of the upper respiratory tract (laryngeal edema). Until now only administration of a purified C1-inhibitor extract was effective against these symptoms. This paper aims to synthesise essentials knowledge concerning news drugs, in particular icatibant, a selective bradykinin B2- receptor antagonist whose use should be widened to the treatment of angioedema with ACE-inhibitors intolerance.
authors.affiliation: Service d'immunologie et d'allergie, CHUV, 1011 Lausanne. annette.leimgruber@chuv.ch
authors.forename: Annette
authors.initials: A
authors.lastname: Leimgruber
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D054179:Angioedemas, Hereditary / Q000188:drug therapy*; D001920:Bradykinin / Q000031:analogs & derivatives / Q000627:therapeutic use; D050718:Complement C1 Inhibitor Protein / Q000627:therapeutic use; D051056:Complement Inactivating Agents / Q000627:therapeutic use; D006801:Humans
chemical_list: D000319:Adrenergic beta-Antagonists; D050718:Complement C1 Inhibitor Protein; D051056:Complement Inactivating Agents; C065679:icatibant; D001920:Bradykinin